Researchers at University of Colorado Cancer Center suggest that physicians should reconsider the criteria used in matching lung cancer with the drug crizotinib as it could leave out some patients who can benefit from the drug, a new study published in the journal Cancer reveals.
The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs....
Researchers at University of Colorado Cancer Center suggest that physicians should reconsider the criteria used in matching lung cancer with the drug crizotinib as it could leave out some patients who can benefit from the drug, a new study published in the journal Cancer reveals.
The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs....